4[1]National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ ). Third report of the national cholesterol education program (NCEP) expertpanel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ ) final report [J].Circulation, 2002, 106:3 143.
5[2]Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease[J] . Heart, 2002, 88:25.
6[3]Saia F, De Feyter P, Serruys PW, et al. Effect of fluvastatin on long - term outcome after coronary revascularization with stent implantation[J]. Am J Cardiol, 2004, 93:92.
7[4]Clearfield M. Evolution of cholesterol management therapies:exploiting potential for further improvement [J]. Am J Ther,2003, 10:275.
8[5]Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J] . N Engl J Med, 2004, 350:1 495.
9[6]Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis [J]. J Am Coll Cardiol, 2000, 35: 1.
10[7]Ridker M, Rifai N, Clearfield M, et al. Measurement of Creactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. Air force/texas coronary atherosclerosis prevention study investigators [J]. N Engl Med,2001, 344:1 959.
